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Abstract Purpose: Experimental
evidence suggests that lactate is neu-
roprotective after acute brain injury;
however, data in humans are lacking.
We examined whether exogenous
lactate supplementation improves
cerebral energy metabolism in
humans with traumatic brain injury
(TBI). Methods: We prospectively
studied 15 consecutive patients with
severe TBI monitored with cerebral
microdialysis (CMD), brain tissue
PO2 (PbtO2), and intracranial pres-
sure (ICP). Intervention consisted of a
3-h intravenous infusion of hyper-
tonic sodium lactate (aiming to
increase systemic lactate to
ca. 5 mmol/L), administered in the
early phase following TBI. We
examined the effect of sodium lactate
on neurochemistry (CMD lactate,
pyruvate, glucose, and glutamate),
PbtO2, and ICP. Results: Treatment
was started on average 33 ± 16 h
after TBI. A mixed-effects multilevel
regression model revealed that
sodium lactate therapy was associated
with a significant increase in CMD
concentrations of lactate [coefficient
0.47 mmol/L, 95 % confidence inter-
val (CI) 0.31–0.63 mmol/L], pyruvate
[13.1 (8.78–17.4) lmol/L], and glu-
cose [0.1 (0.04–0.16) mmol/L; all
p \ 0.01]. A concomitant reduction
of CMD glutamate [-0.95 (-1.94 to
0.06) mmol/L, p = 0.06] and ICP
[-0.86 (-1.47 to -0.24) mmHg,
p \ 0.01] was also observed. Con-
clusions: Exogenous supplemental
lactate can be utilized aerobically as a
preferential energy substrate by the
injured human brain, with sparing of
cerebral glucose. Increased availabil-
ity of cerebral extracellular pyruvate
and glucose, coupled with a reduction
of brain glutamate and ICP, suggests
that hypertonic lactate therapy has
beneficial cerebral metabolic and
hemodynamic effects after TBI.
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Introduction
Mechanisms of secondary cerebral damage after trau-
matic brain injury (TBI) rely on the complex interplay
between cerebral blood flow, oxygen, and energy supply
[1]. Clinical investigations using PET scans and the
cerebral microdialysis (CMD) technique have shown that
TBI is associated with increased cerebral glucose utili-
zation that may eventually culminate into a state of
energy dysfunction [2, 3]. In this setting, the supply to the
injured brain of the main energy substrate—i.e., glucose
[4]—may become limited, leading to reductions of cere-
bral extracellular glucose below critical thresholds, a
scenario which is associated with worse outcome [5, 6].
Experimental evidence repeatedly demonstrated that
the brain can use substrates other than glucose to sustain
increased activity, including lactate [7–11]. Increased
lactate can be the consequence of anaerobic metabolism,
i.e., the formation of lactate in the presence of low oxy-
gen. However, emerging evidence demonstrated that in
patients with TBI increased lactate seems predominantly
non-hypoxic/ischemic and rather the consequence of
increased cerebral glycolysis [2, 12, 13]. Lactate formed
under such glycolytic conditions is shuttled from one
lactate-producing cell (astrocyte) to another lactate-con-
suming cell type (neuron) (astrocyte–neuron lactate
shuttle) [14, 15]. Utilization of lactate as an alternative
fuel may be an adaptive response to maximize energy
function and limit substrate reduction. Uptake of endog-
enous cerebral lactate has indeed been demonstrated after
TBI in animals [16] and in humans [3, 17].
Administration of supplemental lactate significantly
contributes to brain metabolism: at supraphysiologic
concentrations (ca. 5 mmol/L) ‘‘extra’’ lactate becomes
the preferential energy substrate for neurons with sparing
of glucose [18] and might be neuroprotective after
experimental TBI [19]. The ability of the injured brain to
use supplemental lactate as a glucose-sparing fuel may be
important to overcome post-TBI increased energy
demand. To test this hypothesis we designed a prospec-
tive interventional study to examine in patients with TBI
monitored with CMD whether hypertonic lactate ther-
apy—administered intravenously during the acute phase
of injury—might have beneficial effects on cerebral
energy metabolism.
Methods
Study type
This was a prospective phase II interventional study that
was performed at the Department of Intensive Care
Medicine, CHUV, Lausanne, Switzerland. The study was
approved by the Ethical Research Committee of the
University of Lausanne. Informed consent was obtained
from each patient’s next of kin.
Patients
Inclusion criteria
Patients with severe TBI, defined by an admission Glas-
gow Coma Scale (GCS) \ 9, aged 18–60 years, with
abnormal admission brain CT scan (defined by a Marshall
score C2), who underwent intracranial monitoring with
CMD, brain tissue oxygen tension (PbtO2), and intracra-
nial pressure (ICP).
Exclusion criteria
Penetrating TBI, age \18 or [60 years, history of neu-
rological disease, brain death or expected death within
48 h, pregnancy, more than one major extracranial injury
with sustained hemodynamic instability and persistent
elevation of blood lactate [4 mmol/L for [6 h before
intervention, time from TBI to study inclusion [72 h.
Intracranial monitoring
Cerebral microdialysis consisted of a 70 MD bolt catheter
with 20-kDa cutoff (M Dialysis AB, Stockholm, Swe-
den). Microdialysis samples were collected hourly and
analyzed for brain extracellular concentrations of glucose,
lactate, pyruvate, and glutamate. PbtO2 was measured
using a Licox catheter (Integra Neurosciences, Plains-
boro, NJ, USA) calibrated to the patient’s temperature.
Intracranial pressure was measured using a Codman
probe (Raynham, MA, USA). Probes were inserted
through a triple-lumen bolt in the operating room by a
neurosurgeon and placed into the brain parenchyma
(subcortical white matter), in the right frontal lobe. Brain
CT scan was performed at approximately 24 h to confirm
the correct placement of intracranial monitors.
General management
All patients were treated according to a standard protocol
for the management of severe TBI following international
guidelines [20, 21]. Sedation–analgesia consisted of pro-
pofol and sufentanil. All patients were mechanically
ventilated to maintain PaO2 at 90–100 mmHg and PaCO2
at 35–40 mmHg. Brain physiological targets were set to
maintain ICP \ 20 mmHg and cerebral perfusion pres-
sure (CPP = mean arterial pressure, MAP–ICP)
[60 mmHg. Blood glucose was targeted at 6–8 mmol/L.
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Study intervention
The intervention consisted of a continuous infusion of
hypertonic sodium lactate (Na? 1,000 mmol/L, lactate
1,000 mmol/L, prepared by the Division of Pharmacy,
CHUV, Lausanne), administered over 3 h (at 40 lmol/kg/
min for 60 min, followed by 30 lmol/kg/min for an
additional 120 min) started within 72 h from TBI (clini-
caltrials.gov identifier NCT01573507).
Study endpoints
Study efficacy
The treatment aimed to rapidly increase blood arterial lactate
to supraphysiological concentrations (ca. 5 mmol/L) using a
bolus dose over 30 min, followed by a maintenance dose up
to 3 h. This infusion protocol was in line with previous
clinical studies in healthy human subjects [22, 23] and per-
formed according to a previous investigation at our
institution in critically ill non-neurological patients [24]. The
primary endpoint was to analyze the effect of sodium lactate
infusion on CMD concentrations of lactate, pyruvate, and
glucose. Secondary endpoints were to analyze the effect of
lactate therapy on CMD glutamate, PbtO2, and ICP.
Study safety
Safety parameters included blood arterial pH, bicarbon-
ate, sodium, and osmolarity. Safety thresholds were set at
pH [ 7.55, sodium [155 mmol/L, and osmolarity [320
mosm/L.
Data collection and processing
Clinical and radiological variables included age, gender,
admission GCS, Marshall CT scan score [25], type of
injury, time from TBI to intracranial monitoring, and
duration of monitoring. Neurological outcome at 6 months
was assessed using the GOS. Cerebral microdialysis
variables were collected hourly. Main brain physiological
variables (PbtO2, ICP, and CPP) were recorded every 60 s
via a computerized medical chart system (Metavision,
IMD soft, Tel-Aviv, Israel) and were matched at the exact
time of CMD analysis. For PbtO2, data were corrected for
temperature and PaO2. Arterial blood was sampled hourly
for concentration of pH, PaO2, PaCO2, bicarbonate, lac-
tate, glucose, sodium, chloride, and osmolarity.
Statistical analysis
Each patient’s individual response to intervention was
graphically plotted for CMD lactate, pyruvate, and
glucose. Data distribution was tested for each variable and
logarithmic transformation was applied for non-normal
data. Results were expressed as mean ± SD for the two
main conditions, i.e., baseline (immediately before the
start of sodium lactate infusion) and sodium lactate
(maximum increase during intervention).
Data analyzed included CMD (lactate, pyruvate, glu-
cose, glutamate) and main brain physiologic (ICP, PbtO2,
CPP) and systemic (lactate, glucose, pH, bicarbonate,
sodium, chloride, osmolarity) variables. Longitudinal data
analysis was used to account for repeated measures of
physiological variables across different patients over time.
Analysis was conducted using mixed-effects multilevel
regression with time as an independent variable and
allowing it to have a random intercept and a random slope
according to the patient. The same model was also applied
to analyze the data obtained during the 6 h preceding the
intervention, to verify data stability prior to sodium lactate
therapy. Correlations were tested using the Pearson’s cor-
relation coefficient. Statistical analyses were performed
using STATA 12 (STATA Corporation, College Station,
TX, USA), and statistical significance was set at p \ 0.05.
Results
Patient characteristics
From April 2012 to March 2013, a total of 24 consecutive
patients were screened for the intervention, of which 9
were excluded, and 15 patients with isolated severe TBI
were included (Fig. 1). Baseline characteristics of the 15
studied patients are summarized in Table 1. Mean age
was 40 ± 15 years and median admission GCS was 7
(range 3–8). Intracranial monitors were placed close to
each other in the right frontal subcortical white matter in
all patients, in an area that corresponded to visually nor-
mal brain parenchyma on control head CT scan (i.e., not
around a contusion or hematoma, Fig. 2). Median time
from TBI to intracranial monitoring was 6 h (interquartile
range 3–15 h) and patients were monitored for a median
of 4 (3.5–7.0) days. There was no catheter-related com-
plication. At 6 months, 9 patients had a favorable
neurological recovery [Glasgow Outcome Score (GOS) 4
or 5] and 6 patients had an unfavorable outcome
[including 2 with severe disability (GOS 3), 1 with veg-
etative state (GOS 2), and 3 non-survivors (GOS 1)].
Effect of sodium lactate therapy on cerebral variables
Sodium lactate therapy was started 33 ± 16 h from TBI.
Following sodium lactate infusion, blood lactate increased
from a baseline pretreatment value of 1.0 ± 0.4 mmol/L
to a maximum of 6.1 ± 1.6 mmol/L. Each patient’s
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Fig. 1 Study flow chart. A total
of 24 patients with isolated
severe traumatic brain injury
(TBI) were screened over the
1-year study period; 15 patients
were included and concluded
the study
Table 1 Patient characteristics
Patient no. Age
(years)
Gender Admission
GCS
Marshall
score
Injury
type
Time from TBI
to intracranial
monitoring (hours)
Time from TBI
to sodium lactate
therapy (hours)
Duration of
intracranial
monitoring (days)
GOS
(at 6 months)
1 54 F 3 2 Diffuse 13 21 4 4
2 39 M 8 2 Focal 52 57 3 4
3 19 M 6 2 Diffuse 7 24 4 5
4 55 M 8 3 Diffuse 6 20 11 5
5 30 M 7 5 Diffuse 8 30 10 3
6 24 M 6 2 Diffuse 6 34 6 2
7 46 M 8 2 Diffuse 7 66 3 4
8 60 M 8 3 Focal 23 64 5 1
9 24 F 6 2 Diffuse 6 24 3 4
10 41 M 3 2 Diffuse 6 24 8 1
11 24 M 8 2 Diffuse 17 23 3 4
12 52 F 7 2 Diffuse 26 38 4 4
13 24 M 7 3 Diffuse 5 21 4 1
14 60 M 6 2 Diffuse 7 24 4 4
15 55 M 8 6 Diffuse 13 27 11 3
F female, GCS Glasgow Coma Scale, GOS Glasgow Outcome Score, M male, TBI traumatic brain injury
Fig. 2 Location of cerebral
microdialysis and brain tissue
PO2 catheters. a One illustrative
example of probe location in the
right frontal subcortical white
matter, with close positioning of
CMD and brain tissue PO2
catheters (b)
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individual response to intervention for CMD lactate,
pyruvate, and glucose is shown in Fig. 3: sodium lactate
was associated with an increase in CMD concentrations of
lactate (from baseline 3.1 ± 0.6 to a maximum of
5.1 ± 1.4 mmol/L during sodium lactate therapy), CMD
pyruvate (115.6 ± 42.9 vs. 180.2 ± 55.7 lmol/L), and
CMD glucose (1.4 ± 0.9 vs. 2.2 ± 1.0 mmol/L). All
three patients with pretreatment low CMD glucose
(\1 mmol/L) had normalized brain glucose values at the
end of sodium lactate therapy.
Results of mixed-effects analysis for changes of
cerebral variables during intervention are shown in
Table 2. During sodium lactate therapy, we found a sig-
nificant increase in CMD concentrations of lactate
[coefficient 0.47 mmol/L, 95 % confidence interval (CI)
0.31–0.63 mmol/L], pyruvate [13.1 (8.78–17.4) lmol/L],
and glucose [0.1 (0.04–0.16) mmol/L; all p \ 0.01]. A
concomitant decrease of CMD glutamate [-0.95 (-1.94
to 0.06) mmol/L, p = 0.06], PbtO2 [-0.58 (-1.14 to
-0.01) mmHg, p = 0.04], and ICP [-0.86 (-1.47 to
-0.24) mmHg, p \ 0.01] was also observed. The effect
of sodium lactate on ICP reduction was greater in the two
patients who had baseline ICP [ 20 mmHg. Cerebral
perfusion pressure and lactate-to-pyruvate ratio (LPR) did
not change significantly during the intervention. Alto-
gether, our data indicate aerobic utilization of systemic
lactate with sparing of cerebral glucose and overall met-
abolic benefit for brain tissue.
Of note, blood lactate as well as CMD lactate, pyru-
vate, and glucose did not change significantly over the 6 h
prior to sodium lactate infusion (all p [ 0.1, mixed-
effects analysis, see example of an individual patient in
Fig. 4), indicating data stability before treatment start.
Concentrations of CMD lactate, pyruvate, and glucose
returned to baseline values at 6 h post-treatment start.
A majority of patients (10/15, 67 %) displayed baseline
LPR [ 25, a marker of increased energy distress: inter-
estingly, we observed a significant correlation between
LPR and the percentage of CMD pyruvate increase (Pear-
son’s r = 0.60, p = 0.02; Fig. 5), suggesting that
metabolic conversion of lactate into pyruvate during
sodium lactate therapy was more pronounced in patients
who had a higher degree of cerebral energy demand.
Effect of sodium lactate therapy on systemic variables
Results of mixed-effects analysis for changes of systemic
variables during sodium lactate therapy are shown in
Table 2. Blood arterial concentrations of pH, bicarbonate,
sodium, and osmolarity all increased during sodium lac-
tate infusion (all p \ 0.01) and returned to pretreatment
values within 6 h from the end of infusion. Systemic
chloride did not change during treatment. Importantly,
concentrations of systemic glucose did not change sig-
nificantly during sodium lactate therapy (p = 0.39).
Means of other relevant systemic physiological variables
(including MAP, heart rate, body temperature, PaO2, and
PaCO2) were within normal ranges in all patients and a
mixed-effects model did not show significant changes of
these variables during the treatment.
Discussion
The findings of this study can be summarized as follows:
(1) we showed for the first time in humans with acute
Fig. 3 Effect of sodium lactate therapy on cerebral energy
metabolism across individual patients (n = 15). Horizontal lines
illustrate individual baseline and maximum values during sodium
lactate (SL) therapy of cerebral microdialysis (CMD) concentra-
tions of lactate, pyruvate, and glucose. Differences in means (±SD)
of extracellular brain lactate concentration between baseline (left
side of the graphic) versus SL therapy (right side of the graphic) are
also shown (CMD lactate, 3.1 ± 0.6 versus 5.1 ± 1.4 mmol/L;
CMD pyruvate, 115.6 ± 42.9 versus 180.2 ± 55.7 lmol/L; CMD
glucose, 1.4 ± 0.9–2.2 ± 1.0 mmol/L)
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brain injury that exogenous systemic lactate may be uti-
lized aerobically as a preferential energy substrate over
glucose; (2) by increasing the availability of cerebral
extracellular pyruvate and glucose, exogenous lactate
supplementation resulted in improved brain energetics
during the early phase of TBI, (3) hypertonic lactate
Table 2 Changes of main cerebral and systemic variables during sodium lactate therapy
Coefficient ± SE 95 % Confidence interval p value
Cerebral variables
CMD lactate (mmol/L) 0.47 ± 0.08 0.31 to 0.63 \0.01
CMD pyruvate (lmol/L) 13.10 ± 2.20 8.78 to 17.40 \0.01
CMD glucose (mmol/L) 0.10 ± 0.04 0.04 to 0.16 \0.01
CMD glutamate (mmol/L) -0.95 ± 0.51 -1.94 to 0.06 0.06
PbtO2 (mmHg) -0.58 ± 0.29 -1.14 to -0.01 0.04
Intracranial pressure (mmHg) -0.86 ± 0.32 -1.47 to -0.24 \0.01
Systemic variables
Glucose (mmol/L) 0.08 ± 0.09 -0.11 to 0.28 0.39
Sodium (mmol/L) 1.96 ± 0.25 1.48 to 2.44 \0.01
Chloride (mmol/L) -0.08 ± 0.25 -0.57 to 0.42 0.76
pH 0.04 ± 0.01 0.00 to 0.02 \0.01
Osmolarity (mosm/L) 3.57 ± 0.44 2.71 to 4.43 \0.01
Analysis was conducted using mixed-effects multilevel regression with time as an independent variable and allowing it to have a random
intercept and a random slope according to patient
CMD cerebral microdialysis, PbtO2 brain tissue oxygen tension
Fig. 4 Dynamic changes over time of systemic lactate and brain
energy metabolites upon sodium lactate therapy in one represen-
tative patient. The line graph shows the time course in one
illustrative patient of cerebral microdialysis (CMD) glucose, CMD
pyruvate, and systemic and CMD lactate during the 6 h prior to the
intervention, during sodium lactate supplementation (box with
dashed lines), and over the 3 h following the treatment
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therapy was associated with a reduction of ICP and brain
glutamate. Overall our findings suggest that hypertonic
lactate therapy has both a positive effect on cerebral
energy metabolism and on ICP reduction, suggesting that
it may be a valid therapeutic option to test in the future in
patients with TBI.
Evidence of lactate utilization by the injured human
brain
Generally considered as a by-product of anaerobic
metabolism, lactate was shown to support synaptic func-
tion [7] and to act as an alternative substrate to glucose
[8–10]. Evidence of endogenous lactate utilization has
been provided in humans with TBI [12] and subarachnoid
hemorrhage (SAH) [26]. This may be important after TBI,
where utilization of the predominant brain substrate
(glucose) can be dramatically increased [2, 3, 27], leading
to reduced glucose availability and worse outcome [5, 6].
We showed that supplemental lactate from the sys-
temic circulation may be converted by the brain into
pyruvate, and we found that cerebral pyruvate increase
was proportionate to the extent of cerebral energy dys-
function. Importantly, pyruvate increase was coupled with
a moderate but statistically significant decrease of PbtO2,
whereas LPR remained stable during sodium lactate
therapy. PbtO2 is equal to the product of CBF with the
difference between PaO2 and PvO2 [28]. During the
study, CPP, PaCO2, MAP, and temperature (all major
determinants of CBF) did not change. PaO2 also was kept
stable throughout the study. Actually, in a subset of
patients (n = 6) in whom transcranial Doppler was
measured during sodium lactate infusion, a significant
increase in CBF velocities was found (data not shown), in
line with experimental findings showing that lactate can
act as local cerebral vasodilator [29]. Therefore, we can
conclude that the observed reduction of PbtO2 is sec-
ondary to a decrease in PvO2, indicating increased oxygen
extraction by the tissue. These findings suggest that lac-
tate was actively converted into pyruvate to be utilized
aerobically by the injured human brain. Additional issues
warrant further discussion. The first pertains to the rela-
tionship between lactate and oxygen. Lactate can increase
as a consequence of anaerobic glycolysis, where
increased lactate production is due to insufficient oxygen
availability that will hamper the Krebs cycle metabolism
of pyruvate. Under such conditions, exogenously admin-
istered lactate cannot be metabolized further. However,
emerging clinical data suggest that lactate increase is
mainly non-hypoxic in patients with TBI [13, 30, 31]. In
the present study, TBI patients did not display low PbtO2,
meaning that the administered lactate could indeed be
converted to pyruvate, which is subsequently metabolized
via the TCA cycle and the associated ATP-generating
oxidative phosphorylation. This metabolic sequence
occurs under normoxic conditions, and is also known as
the Warburg effect [32]. In our study, lactate is provided
exogenously under essentially normoxic conditions,
which allows its utilization by lactate-consuming brain
cells to produce ATP. The second issue relates to cerebral
extracellular pyruvate increase. It should be kept in mind
that the concentrations of lactate are about 10 times
higher than those of pyruvate (2–3 mmol/L vs. 100 lmol/
L). Thus, given the mass action effect, the normoxic
conditions (which allow conversion of lactate to pyruvate)
and the relative kinetic properties of lactate dehydroge-
nase (LDH) type A and pyruvate dehydrogenase, it is not
surprising that more pyruvate is formed that can be
metabolized through the TCA cycle, thereby resulting in a
net increase of CMD pyruvate concentrations.
Lactate supplementation is associated with sparing
of cerebral glucose
Sparing of cerebral glucose was demonstrated by the
concomitant increase of CMD glucose concentration.
Given that systemic glucose did not change during
sodium lactate infusion, the observed increase of CMD
glucose can only be attributable to preferential lactate
utilization over glucose by the injured brain. Our study
confirms previous experimental data and studies in heal-
thy humans [18, 23]. Increasing the availability of
cerebral glucose is important in the setting of human TBI
where reductions of CMD glucose are frequent and are
associated with worse prognosis [5, 6]. Restoration of
cerebral glucose reserves by hypertonic lactate therapy
indeed appears to be of benefit in the setting of TBI.
Glucose is the essential substrate for brain metabolism,
Fig. 5 Lactate conversion to pyruvate is proportional to baseline
cerebral energy demand. The graph shows the positive linear
correlation between baseline lactate-to-pyruvate ratio (marker of
cerebral energy demand) and the extent of CMD pyruvate increase
(delta brain pyruvate, expressed in % increase from baseline)
observed during sodium lactate infusion (n = 15 patients with
severe TBI; Pearson’s r = 0.60, p = 0.02)
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participating in bioenergetics, reactive oxygen species
regulation, neurotransmission, and biosynthesis [33]. The
use of lactate as an alternative energy fuel could enable
extra glucose to be available during the early phase of
injury for these important rescue processes.
Additional effects of sodium lactate supplementation
Sodium lactate therapy was associated with a reduction of
brain glutamate, which almost reached statistical signifi-
cance (p = 0.06). Given that glutamate was stable prior to
sodium lactate therapy, we considered the observed glu-
tamate decrease as physiologically and clinically relevant.
Glutamate accounts for 80–90 % of the synapses in the
brain and is the major excitatory neurotransmitter. The
concentration of glutamate into the synaptic space rises
dramatically after TBI, and failure of astrocytes to remove
this excess of extracellular glutamate might lead to
excitotoxic damage and neuronal death [34]. Increased
glutamate release is a concomitant marker of energy
failure; thus, providing energy in the form of lactate
would allow neurons to control glutamate release and
prevent glutamate ‘‘leak’’. Lactate supplementation leads
to increased glucose availability to sustain glutamate
uptake in astrocytes.
Sodium lactate infusion also resulted in a significant
reduction of ICP, which was most marked in patients with
intracranial hypertension, further substantiating the view
that hypertonic lactate may be a valid therapeutic option
after TBI. Since the majority of patients did not have
elevated ICP, additional studies are needed to confirm the
effect of hypertonic lactate solutions in patients with
intracranial hypertension. Lactate was administered as a
hypertonic solution; therefore, we cannot completely rule
out a potential anti-edematous effect: further discrimina-
tion between the metabolic and the anti-edematous effect
of hypertonic lactate solutions requires future studies
comparing hypertonic lactate to hypertonic saline.
Clinical implications of the study
Sodium lactate may be used for volume resuscitation,
providing positive effects on brain energy metabolism,
while avoiding adverse effects (hyperchloremic acidosis)
of other standard resuscitative solutions, such as sodium
chloride [35]. Hypertonic lactate could be an alternative
for the treatment of intracranial hypertension [36, 37].
Altogether the findings of this prospective interventional
study warrant further clinical investigation in a larger
setting to confirm whether sodium lactate therapy is
beneficial in patients with TBI and other forms of acute
cerebral diseases, and to compare the effects of hyper-
tonic lactate versus standard hypertonic saline solutions
for the treatment of intracranial hypertension.
Study limitations
The main limitation of this study is the small sample size.
However the cohort consisted of a homogenous group of
patients with isolated severe TBI, with predominantly dif-
fuse injury, who were all monitored in the same tissue
region and were treated with a standardized algorithm. The
time from TBI to sodium lactate therapy was variable
among patients; however, this did not influence the results.
Lactate therapy was given over a limited period of time
(3 h). This was mainly to limit the potential side effects
(hypernatremia, increased osmolarity, metabolic alkalo-
sis), the relevance of which is unclear. Although the main
relevant systemic physiological variables (MAP, heart rate,
body temperature, PaO2, and PaCO2) did not change over
time, we cannot entirely exclude potential confounders;
therefore, our findings in this small cohort of patients must
be considered as preliminary. Additional limitations
include that brain metabolism was measured using CMD
and PbtO2, i.e., with focal monitoring. This approach has
several advantages, e.g., it allows the monitoring of
dynamic changes of different brain metabolites upon ther-
apy and it is accessible at the bedside. However, we did not
use PET scans in this study and therefore we cannot provide
global measurement of cerebral lactate uptake and CMRO2.
Despite these technical limitations, we believe that com-
bined monitoring of CMD, PbtO2, and ICP provided us with
essential tools to test the dynamic changes of cerebral
energy metabolism following sodium lactate therapy.
Conclusions
We showed that exogenous systemic lactate is utilized by
the injured human brain as a preferential energy substrate
with subsequent sparing of cerebral glucose. The increase
of pyruvate and glucose in brain interstitial tissue—
together with the decrease of cerebral glutamate and
intracranial pressure—suggests that hypertonic lactate
therapy has positive effects on cerebral energy metabo-
lism and on ICP reduction in the early phase following
TBI. Our findings support further investigation to test the
value of this therapeutic strategy in patients with acute
brain injury and to evaluate whether the observed cerebral
biochemical and physiological effects of hypertonic lac-
tate might translate into a better neurological outcome.
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